|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus
Cecilia Monge Bonilla 1 , Nicole A McGrath 1 , Jianyang Fu 1 , Changqing Xie 1
Affiliations
Affiliation
1
Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
PMID: 33134550 PMCID: PMC7597818 DOI: 10.20517/2394-5079.2020.58
Free PMC article
Abstract
Hepatocellular carcinoma (HCC) has one of highest mortalities globally amongst cancers, but has limited therapeutic options once in the advanced stage. Hepatitis B or C virus infection are the most common drivers for HCC carcinogenesis, triggering chronic liver inflammation and adding to the complexity of the immune microecosystem of HCC. The emergence of immunotherapy has afforded a new avenue of therapeutic options for patients with advanced HCC with a history of hepatitis B or C virus infection. This article reviews the change of immunity elicited by hepatitis B or C virus infection, the immune feature of HCC, and the clinical evidence for immunotherapy in advanced HCC and discusses future directions in this field.
Keywords: Hepatocellular carcinoma; hepatitis B virus; hepatitis C virus; immunotherapy.
|
|
发表于 2020-11-4 09:45
